

5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I

Andreas Schmidt^{a,1}, Tobias Schwerd^{a,1}, Wolfgang Hamm^{a,1}, Johannes C. Hellmuth^a, Sheng Cui^b, Michael Wenzel^a, Franziska S. Hoffmann^a, Marie-Cecile Michallet^c, Robert Besch^d, Karl-Peter Hopfner^b, Stefan Endres^a, and Simon Rothenfusser^{a,e,2}

^aDivision of Clinical Pharmacology, Department of Medicine, Ludwig-Maximilian University Munich, 80336 Munich, Germany; ^bCenter for Integrated Protein Sciences, Department of Chemistry and Biochemistry, Gene Center, Ludwig-Maximilian University Munich, 81377 Munich, Germany; ^cDepartment of Dermatology and Allergology and ^eSection Gastroenterology and Endocrinology, Medizinische Klinik Innenstadt, Ludwig-Maximilian University Munich, 80337 Munich, Germany; and ^dDepartment of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland

Edited by Charles A. Dinarello, University of Colorado Health Sciences Center, Denver, CO, and approved May 26, 2009 (received for review January 29, 2009)

The ATPase retinoid acid-inducible gene (RIG)-I senses viral RNA in the cytoplasm of infected cells and subsequently activates cellular antiviral defense mechanisms. RIG-I recognizes molecular structures that discriminate viral from host RNA. Here, we show that RIG-I ligands require base-paired structures in conjunction with a free 5'-triphosphate to trigger antiviral signaling. Hitherto unavailable chemically synthesized 5'-triphosphate RNA ligands do not trigger RIG-I-dependent IFN production in cells, and they are unable to trigger the ATPase activity of RIG-I without a base-paired stretch. Consistently, immunostimulatory RNA from cells infected with a virus recognized by RIG-I is sensitive to double-strand, but not single-strand, specific RNases. In vitro, base-paired stretches and the 5'-triphosphate bind to distinct sites of RIG-I and synergize to trigger the induction of signaling competent RIG-I multimers. Strengthening our model of a bipartite molecular pattern for RIG-I activation, we show that the activity of supposedly "single-stranded" 5'-triphosphate RNAs generated by in vitro transcription depends on extended and base-paired by-products inadvertently, but commonly, produced by this method. Together, our findings accurately define a minimal molecular pattern sufficient to activate RIG-I that can be found in viral genomes or transcripts.

immunostimulatory RNA | melanoma differentiation-associated protein 5 | retinoid acid-inducible gene-I-like helicases | virus infection | interferon production

Viral infections are sensed by pattern-recognition receptors (PRRs) of the innate immune system that recognize pathogen-associated molecular patterns (PAMPs), and trigger antiviral gene programs, including the production of IFN type-I (1). Viral RNA serves as a PAMP and can be recognized by toll-like receptor (TLR)-3, TLR-7/8, double-stranded (ds)RNA-activated protein kinase (PKR), and the retinoid acid-inducible gene (RIG)-I-like helicase (RLH) family members RIG-I, melanoma differentiation-associated protein 5 (MDA-5), and laboratory of genetics and physiology (Lgp)2 (2–4). There is evidence that RIG-I signals on infection by many RNA viruses, including important human pathogens (5, 6). After ligand-mediated activation critically involving ATPase activity and the C-terminal regulatory domain (RD) RIG-I binds via its amino-terminal caspase-activation and recruitment domain (CARD) to the adaptor protein Cardif (MAVS, VISA, Ips-1) that then triggers the NF κ B and IRF signaling pathways (7). The exact nature of the PAMP that allows RIG-I to discriminate viral from host RNA in the cytosol is highly controversial. Kim et al. (8) have shown that RNA produced by in vitro transcription (IVT) bearing a 5'-triphosphate end is able to trigger IFN production in cells. Thereafter, our laboratory and others have reported that an essential feature of the viral RNA ligand of RIG-I is a free 5'-triphosphate that is absent from host cytoplasmic RNA due to eukaryotic RNA metabolism (9, 10). Using 5'-triphosphate RNAs produced by IVT, these studies concluded that both single-stranded (ss) and dsRNAs activate RIG-I as long as they carry the 5'-triphosphate (8–10). The RD of RIG-I has subsequently been

characterized as the structural entity that binds 5'-triphosphate and, thus, aids in defining ligand specificity (11, 12). However, the concept that the 5'-triphosphate modification in cytosolic RNA represents the complete PAMP recognized by RIG-I was challenged recently by several prominent studies, suggesting that (i) 3'-monophosphate RNAs, as produced by RNase L, might be RIG-I ligands (13); (ii) a 5'-triphosphate end is dispensable if the RNA ligand is double stranded and carries either 5'-monophosphates or is long enough (12, 14); and (iii) RIG-I ligands require uridine- or adenosine-rich sequences (15). These reports raise the question whether the 5'-modification with (tri)phosphate is sufficient, merely required, or in some cases dispensable for physiological RIG-I ligands. For this report, we have investigated the structural requirements to activate RIG-I-mediated antiviral signaling using defined ligands including synthetic 5'-triphosphate RNA.

Results

Ligand-Induced ATPase Activity Is Triggered by a Feature Other than the 5'-Triphosphate Moiety. Previous studies have shown that short 5'-triphosphate RNAs of 19 to 21 bases generated by IVT are potent RIG-I ligands that induce IFN in human monocytes independently of TLRs (8–10). To identify a minimal pattern sufficient to trigger RIG-I signaling, we analyzed different versions of a 19-mer model-RNA named 2.2 (Table S1). The chemically synthesized 5'-OH version of ss2.2 sense (s) RNA, its complementary antisense (as) strand, and their annealed base-paired version (ds2.2) failed to induce IFN- α when transfected into human monocytes (Fig. 1A). However, as expected from previous studies, IVT (5'-triphosphate) 2.2 RNA induced strong IFN production either as ssRNA (ss2.2s) or as dsRNA (ds2.2) (Fig. 1A). Of note, in our hands, chemically synthesized ds or ss 3'- or 5'-monophosphorylated RNAs did not show significant immunostimulatory activity when we transfected them into human monocytes using the 2.2 sequence or a 25-mer sequence published to be active in mouse cells by Takahasi et al. (Fig. S1A) (12). However, they were active when transfected into human PBMCs containing plasmacytoid dendritic cells, indicating that these RNAs can be recognized by a different

Author contributions: A.S., T.S., W.H., J.C.H., S.C., K.-P.H., S.E., and S.R. designed research; A.S., T.S., W.H., J.C.H., S.C., M.W., and F.S.H. performed research; M.-C.M., R.B., and K.-P.H. contributed new reagents/analytic tools; A.S., T.S., W.H., J.C.H., S.C., M.W., F.S.H., R.B., S.E., and S.R. analyzed data; and A.S., S.E., and S.R. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Freely available online through the PNAS open access option.

¹A.S., T.S., and W.H. contributed equally to this work.

²To whom correspondence should be addressed. E-mail: simon.rothenfusser@med.uni-muenchen.de.

This article contains supporting information online at www.pnas.org/cgi/content/full/0900971106/DCSupplemental.




Fig. 2. 5'-triphosphate RNAs generated by IVT contain base-paired by-products that activate RIG-I. (A) Chemically synthesized 5'-OH-ssRNAs and 5'-ppp-ss2.2 RNAs generated by IVT were analyzed by denaturing gel electrophoresis and ethidium bromide (EtdBr) staining. Products of the expected (lower arrow in all samples), and unexpected (upper arrow in lanes containing 5'-ppp-RNA generated by IVT) size were reisolated for further analysis. (B) Reisolated IVT products were compared with 5'-OH-ss2.2as RNA and unpurified 5'-ppp-ss2.2as (IVT) RNA, for their ability to induce IFN- α production in human monocytes. (C) Stimulation of ATPase activity of recombinant, full-length RIG-I protein with reisolated and control RNAs. (D) Clones 1 and 9 are 2 RNA-sequences identified by 5'-ppp-ss2.2 RNA (IVT) small RNA cloning and sequencing. Nucleotides not encoded by the DNA template are indicated in red. Also, the sequence of a designed hairpin RNA (hp2.2s/as) based on the 2.2 model sequence is displayed. Secondary structures (minimum free energy) of clone 1, clone 9, and hp2.2s/as are as predicted by the Mfold software (21). (E) RNAs of clone 1, clone 9, and hp2.2s/as were generated by IVT and transfected into human monocytes. Production of IFN- α was measured by ELISA after 36 h. (F) The 1205Lu human melanoma cells were treated with the indicated siRNAs for 48 h and subsequently transfected with the indicated RNAs; 12 h after stimulation, supernatants were subjected to IP10 analysis by ELISA.

we resorted to defined, chemically synthesized 5'-triphosphate RNA (syn-ppp-ss2.2s). Of note, the production of 5'-triphosphate RNAs by nonenzymatic chemistry is a challenge, and these reagents were not available so far. We consistently found that syn-ppp-ss2.2s RNA, which like the expected IVT product of 2.2s cannot form stable secondary structures, was unable to induce IFN in cells (Fig. 3A Left). However, annealing of a complementary 5'-OH strand (5'-OH-ss2.2as) before transfection rescued IFN production, indicating that a base-paired structure was necessary and, together with a 5'-triphosphate, sufficient to trigger RIG-I (Fig. 3A Left). Thus, formation of a loop structure was dispensable in this system. Still, a chemically synthesized 5'-triphosphate hairpin RNA (syn-ppp-2.2hp) designed to incorporate base-paired secondary structure and 5'-triphosphate into one molecule lead to high-level IFN induction in human monocytes (Fig. 3A Right). Importantly, the corresponding 2.2 hairpin RNA lacking a 5'-triphosphate did not induce IFN (Fig. 3A Right). Signaling of chemically synthesized 5'-triphosphate RNAs showed the same RIG-I-dependence seen before with ligands generated by IVT (Fig. 3D; Fig. S4 A and B). Assaying RIG-I ATPase activity of the chemically produced ligands showed that only base-paired, but not unstructured 5'-triphosphate RNA, can induce ATP hydrolysis (Fig. 3B). This difference in activity was not due to a higher stability of base-paired RNA, because neither ssRNA nor dsRNA showed degradation under assay conditions (Fig. S4C). These results support our hypothesis and provide proof that the 5'-triphosphate end is not sufficient to mediate RNA-induced RIG-I activation and cannot trigger ATPase activity on its own.

To define the structural requirements for RIG-I activation in more detail, we hybridized successively longer 5'-OH-RNAs com-

plementary to the 3'- or 5'-end of syn-ppp-ss2.2s RNA, and tested their ability to induce IFN production in monocytes and ATPase activity of recombinant RIG-I. When oligonucleotides of 5-, 10-, or 15-nts length were hybridized to syn-ppp-ss2.2s RNA from the 3'-end, no IFN production was observed (Fig. 3C); only fully complementary RNA (Fig. 3A) or an 18-mer hybridized to the 3'-end of syn-ppp-ss2.2s RNA could rescue IFN production (Fig. 3C). However, when 5-, 10-, or 15-nts complementary RNA were hybridized to the 5'-end of syn-ppp-ss2.2s RNA, 10 nts were sufficient to rescue IFN induction, suggesting that the extent of base-pairing as well as its relative position to the 5'-triphosphate-end are important determinants of immunostimulatory activity (Fig. 3C). Assaying the same set of RNAs for ATPase activity showed that ATP-hydrolysis depended on a base-paired stretch of >5 nts, but was independent of its relative position to or the presence of the 5'-triphosphate (Fig. 3E). Interestingly, complementary strands producing a short 3'-overhang at the 5'-triphosphate-bearing end of the oligonucleotide supported RIG-I ATPase activity, but did not induce IFN. The short overhang in direct proximity to the 5'-triphosphate group seemed to interfere with its correct recognition, highlighting the importance of a free 5'-triphosphate for signaling activity (Fig. S5 A and B). Together, these results show that a 5'-triphosphate modification on RNA is not sufficient to activate RIG-I signaling. They support a model in which a minimal pattern that can be recognized by RIG-I is a rather small stretch of base-paired RNA in addition to a 5'-triphosphate group. Of note, this finding does not seem to be an effect that is observed exclusively with short RNAs below 20 bases. A 70-mer RNA designed not to form secondary structures (Table S1) is

isolated from virus-infected cells remains immunostimulatory when treated with a ss specific RNase, but not when base-paired RNA is digested. Recently, it was suggested that viral RNA requires A- or U-rich stretches to activate RIG-I (15). The mechanism of sequence-specific ligand recognition has not been investigated in this context. We did not systematically test the influence of sequence content on RIG-I activation. However, the different short sequences we found to be active were neither A nor U rich (<50% A plus U). Therefore, the ligand features that have been identified by Saito et al. (15) may certainly be highly relevant in the context of HCV recognition, but do not seem to present a generalized structural motif that explains RIG-I ligand recognition. Our biochemical binding and competition data suggest that 5'-triphosphate end and base-paired stretch, the 2 parts of the PAMP, bind distinct sites on RIG-I. Even though the functional cellular assays clearly prove that only a bipartite ligand induces changes in RIG-I that lead to a signaling-competent complex, at the moment, we can only speculate on the nature of these changes. A parallel study showing that RIG-I translocates along dsRNA after binding the 5'-triphosphate provides a further important piece in the puzzle (32). In the future, the structural analysis of RIG-I protein with synthetic RNA ligands will provide us with more information on RIG-I activation mechanisms.

Materials and Methods

RNAs. RNAs (unmodified, monophosphate, and siRNA) and DNAs were purchased from Metabion. Eurogentec kindly produced the chemically synthesized 5'-triphosphate RNA (for details, see *SI Methods*). In vitro transcribed RNAs were synthesized by using the Megashortscript kit (Ambion). DNA templates were generated as previously described (9). RNAs were extracted with phenol/chloroform, precipitated with ethanol, and passed through a Mini Quick Spin Column (Roche). The treatment of IVT RNA with CIAP was carried out as in Hornung et al. (9). Small interfering RNA was applied to 1205Lu cells at 30 nM with Lipofectamine RNAiMax (Invitrogen) as a transfection reagent. After 48 h, the culture medium was exchanged, and cells were stimulated. For a detailed list of all RNA oligonucleotides used for stimulation, see *Table S1*. For DNA templates and primers, see *Table S2*, and for the siRNAs, see *Table S3*.

Cell Stimulation and Cytokine Measurement. Unless indicated otherwise, all primary cells and cell lines were stimulated at 200 ng/mL RNA using Lipofectamine 2000 according to the manufacturer's manual. The 1205LU cells were transfected with Lipofectamine RNAiMax. R848 was from 3M Pharmaceuticals. IFN- α was measured 36 h after stimulation in the supernatant of human monocytes, PBMCs, and murine dendritic cells using the IFN- α module set from Bender MedSystems

and PBL, respectively. Human IP10 was analyzed 12 h after stimulation in the culture medium of 1205LU cells using the opteia set from BD. Induction of the IFN- β promoter was detected with a reporter assay in HEK 293 cells as described in Rothenfusser et al. (3); 24 h after transfection, the cells were stimulated with the indicated RNA oligonucleotides for 12 h.

Recombinant Protein and ATPase Activity Assay. The ATPase activity of recombinant, purified RIG-I-protein was measured using the ADP Quest H5 Assay (DiscoverRx). Full-length RIG-I was expressed in insect cells and purified as described previously (11). The reaction mixture was prepared on ice in a total volume of 10 μ L, containing 1 ng/ μ L purified RIG-I-protein, 1 ng/ μ L purified RNA oligonucleotide, and 100 μ M ATP. Reactions were initiated by the addition of ATP and incubated for 2 h at 37 $^{\circ}$ C.

Isolation and Purification of RNA from Polyacrylamide Gels. Stained RNA bands of interest were cut out on a UV table. The gel slices were fragmented, and the RNA was eluted by adding elution buffer (0.5 M ammonium acetate/1 mM EDTA/0.2% SDS) for 12 h at 37 $^{\circ}$ C. Subsequently, the eluted RNA was extracted and precipitated as described above.

Size-Exclusion Chromatography. All experiments were carried out at room temperature, using a GE Ectan LC system equipped with a Superose 6 PC 3.2/30 (GE Healthcare) size-exclusion column. The size-exclusion column was equilibrated with buffer containing 30 mM Tris-HCl, pH 7.5/150 mM NaCl/2 mM DTT/10 μ M ZnCl₂. After sample injection, UV absorption at both 260 and 280 nm wavelength was recorded. The column was calibrated with Gel Filtration Standard (Bio-Rad) before use.

Fluorescence Anisotropy Measurement. Fluorescence anisotropy experiments were performed with a FluoroMax-P fluorimeter (Horiba Jobin Yvon); 1 mL of buffer (30 mM Tris-HCl, pH 7.5/150 mM NaCl/5 mM 2-mercaptoethanol/10 μ M ZnCl₂) and indicated amounts of fluorescently labeled RNA (in vitro transcribed hp2.2s/as RNA with incorporated Alexa Fluor 488-5-UTP) were preequilibrated in a quartz cuvette at 12 $^{\circ}$ C. Recombinant protein and competitor RNAs were added in a stepwise manner and mixed by gentle pipetting. Preequilibration was used until anisotropy signals were stabilized. The anisotropy data were collected using an excitation wavelength of 495 nm and monitoring the emission at 516 nm. A maximum number of 10 repeats were performed until <2% deviation of the signal was reached.

ACKNOWLEDGMENTS. We thank M. Linke and M. Ruesenberger from Eurogentec for organizing the synthesis of 5'-ppp-RNAs, Gerhard Steger for insightful discussions on RNA structure, and Julia Vorac and Simone Willms for excellent technical assistance. This work was supported by Deutsche Forschungsgemeinschaft Grants DFG RO 2525/3-1 (to S.R.), DFG GK 1202 (to T.S., W.H., J.C.H., S.R., R.B., and S.E.), and LMUexcellent (Center for Integrated Protein Science Munich 114, research professorship), Sonderforschungsbereich-TR 36, and EN 169/7-2 (to S.E.). This work is part of the thesis of T.S., W.H., and J.C.H. at the Ludwig-Maximilian University Munich.

1. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. *Cell* 124:783–801.
2. Andrejeva J, et al. (2004) The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. *Proc Natl Acad Sci USA* 101:17264–17269.
3. Rothenfusser S, et al. (2005) The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. *J Immunol* 175:5260–5268.
4. Yoneyama M, et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat Immunol* 5:730–737.
5. Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K (2006) EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. *EMBO J* 25:4207–4214.
6. Sumpter R, Jr, et al. (2005) Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. *J Virol* 79:2689–2699.
7. Hiscott J, Lin R, Nakhaei P, Paz S (2006) MasterCARD: A priceless link to innate immunity. *Trends Mol Med* 12:53–56.
8. Kim DH, et al. (2004) Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. *Nat Biotechnol* 22:321–325.
9. Hornung V, et al. (2006) 5'-Triphosphate RNA is the ligand for RIG-I. *Science* 314:994–997.
10. Pichlmair A, et al. (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* 314:997–1001.
11. Cui S, et al. (2008) The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I. *Mol Cell* 29:169–179.
12. Takahashi K, et al. (2008) Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. *Mol Cell* 29:428–440.
13. Malathi K, Dong B, Gale M, Jr, Silverman RH (2007) Small self-RNA generated by RNase L amplifies antiviral innate immunity. *Nature* 448:816–819.
14. Kato H, et al. (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. *J Exp Med* 205:1601–1610.
15. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M (2008) Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. *Nature* 454:523–527.
16. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science* 303:1529–1531.
17. Hornung V, et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. *Nat Med* 11:263–270.
18. Cazenave C, Uhlenbeck OC (1994) RNA template-directed RNA synthesis by T7 RNA polymerase. *Proc Natl Acad Sci USA* 91:6972–6976.
19. Nacheva GA, Berzal-Herranz A (2003) Preventing nondesired RNA-primed RNA extension catalyzed by T7 RNA polymerase. *Eur J Biochem* 270:1458–1465.
20. Behrens SE, Tomei L, De Francesco R (1996) Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. *EMBO J* 15:12–22.
21. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res* 31:3406–3415.
22. Kato H, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 441:101–105.
23. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR (2006) Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. *J Virol* 80:5059–5064.
24. Schlee M, et al. (2009) Approaching the RNA ligand for RIG-I? *Immunol Rev* 227:66–74.
25. Leppert M, Kort L, Kolakofsky D (1977) Further characterization of Sendai virus DI-RNAs: A model for their generation. *Cell* 12:539–552.
26. Zhong W, et al. (1999) Nucleoside triphosphatase and RNA helicase activities associated with GB virus B nonstructural protein 3. *Virology* 261:216–226.
27. Gitlin L, et al. (2006) Essential role of mda-5 in type I IFN responses to polyribonucleosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. *Proc Natl Acad Sci USA* 103:8459–8464.
28. Yoneyama M, et al. (2005) Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. *J Immunol* 175:2851–2858.
29. Durr H, Flaus A, Owen-Hughes T, Hopfner KP (2006) Snf2 family ATPases and DExx box helicases: Differences and unifying concepts from high-resolution crystal structures. *Nucleic Acids Res* 34:4160–4167.
30. Ranjith-Kumar CT, et al. (2008) Agonist and antagonist recognition by RIG-I, a cytoplasmic innate immunity receptor. *J Biol Chem* 284:1155–1165.
31. Plumet S, et al. (2007) Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response. *PLoS ONE* 2:e279.
32. Myong S, et al. (2009) Cytosolic viral sensor RIG-I is a 5'-triphosphate-dependent translocase on double-stranded RNA. *Science* 323:1070–1074.